ANIX

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Its therapeutic portfolio includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center, utilizing chimeric endocrine receptor-T cell (CER-T) technology. Anixa also develops cancer vaccines in partnership with Cleveland Clinic, targeting breast and ovarian cancer, as well as other cancers such as lung, colon, and prostate. The company partners with research institutions to advance its technologies through various stages of development and commercialization.